Purpose: The aberrant expression of miR-221 is a hallmark of human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with a proved in vivo efficacy of anti-miR-221 molecules, strengthen its role as an attractive target candidate in the oncologic field. The discovery of biomarkers predicting the response to treatments represents a clinical challenge in the personalized treatment era. This study aimed to investigate the possible role of miR-221 as a circulating biomarker in HCC patients undergoing sorafenib treatment as well as to evaluate its contribution to sorafenib resistance in advanced HCC. Experimental Design: A chemically induced HCC rat model and a xenograft mouse model, together with HCC-derived cell lines were employed to analyze miR-221 modulation by Sorafenib treatment. Data from the functional analysis were validated in tissue samples from surgically resected HCCs. The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC. Results: MiR-221 over-expression was associated with Sorafenib resistance in two HCC animal models and caspase-3 was identified as its target gene, driving miR-221 anti-apoptotic activity following Sorafenib administration. Lower pre-treatment miR-221 serum levels were found in patients subsequently experiencing response to Sorafenib and an increase of circulating miR-221 at the two months assessment was observed in responder patients. Conclusions: MiR-221 might represent a candidate biomarker of likelihood of response to Sorafenib in HCC patients to be tested in future studies. Caspase-3 modulation by miR-221 participates to Sorafenib resistance.

In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis / Fornari, Francesca; Pollutri, Daniela; Patrizi, Clarissa; La Bella, Tiziana; Marinelli, Sara; Casadei Gardini, Andrea; Marisi, Giorgia; Baron Toaldo, M.; Baglioni, Michele; Salvatore, Veronica; Callegari, Elisa; Baldassarre, Maurizio; Galassi, Marzia; Giovannini, Catia; Cescon, Matteo; Ravaioli, Matteo; Negrini, Massimo; Bolondi, Luigi; Gramantieri, Laura. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 23:(2017), pp. 3953-3965. [10.1158/1078-0432.CCR-16-1464]

In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis

Patrizi, Clarissa;Casadei Gardini, Andrea;Baldassarre, Maurizio;
2017

Abstract

Purpose: The aberrant expression of miR-221 is a hallmark of human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with a proved in vivo efficacy of anti-miR-221 molecules, strengthen its role as an attractive target candidate in the oncologic field. The discovery of biomarkers predicting the response to treatments represents a clinical challenge in the personalized treatment era. This study aimed to investigate the possible role of miR-221 as a circulating biomarker in HCC patients undergoing sorafenib treatment as well as to evaluate its contribution to sorafenib resistance in advanced HCC. Experimental Design: A chemically induced HCC rat model and a xenograft mouse model, together with HCC-derived cell lines were employed to analyze miR-221 modulation by Sorafenib treatment. Data from the functional analysis were validated in tissue samples from surgically resected HCCs. The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC. Results: MiR-221 over-expression was associated with Sorafenib resistance in two HCC animal models and caspase-3 was identified as its target gene, driving miR-221 anti-apoptotic activity following Sorafenib administration. Lower pre-treatment miR-221 serum levels were found in patients subsequently experiencing response to Sorafenib and an increase of circulating miR-221 at the two months assessment was observed in responder patients. Conclusions: MiR-221 might represent a candidate biomarker of likelihood of response to Sorafenib in HCC patients to be tested in future studies. Caspase-3 modulation by miR-221 participates to Sorafenib resistance.
2017
17-gen-2017
23
3953
3965
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis / Fornari, Francesca; Pollutri, Daniela; Patrizi, Clarissa; La Bella, Tiziana; Marinelli, Sara; Casadei Gardini, Andrea; Marisi, Giorgia; Baron Toaldo, M.; Baglioni, Michele; Salvatore, Veronica; Callegari, Elisa; Baldassarre, Maurizio; Galassi, Marzia; Giovannini, Catia; Cescon, Matteo; Ravaioli, Matteo; Negrini, Massimo; Bolondi, Luigi; Gramantieri, Laura. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 23:(2017), pp. 3953-3965. [10.1158/1078-0432.CCR-16-1464]
Fornari, Francesca; Pollutri, Daniela; Patrizi, Clarissa; La Bella, Tiziana; Marinelli, Sara; Casadei Gardini, Andrea; Marisi, Giorgia; Baron Toaldo, M.; Baglioni, Michele; Salvatore, Veronica; Callegari, Elisa; Baldassarre, Maurizio; Galassi, Marzia; Giovannini, Catia; Cescon, Matteo; Ravaioli, Matteo; Negrini, Massimo; Bolondi, Luigi; Gramantieri, Laura
File in questo prodotto:
File Dimensione Formato  
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.47 MB
Formato Adobe PDF
1.47 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
1078-0432.CCR-16-1464.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 4.79 MB
Formato Adobe PDF
4.79 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1177515
Citazioni
  • ???jsp.display-item.citation.pmc??? 82
  • Scopus 135
  • ???jsp.display-item.citation.isi??? 124
social impact